Nonadherence Among HIV-Infected Injecting Drug Users: The Impact of Social Instability

Bouhnik, Anne-Déborah; Chesney, Margaret A.; Carrieri, Patrizia; Gallais, H; Moreau, Jacques; Moatti, Jean‐Paul; Obadia, Yolande; Spire, Bruno

doi:10.1097/00126334-200212153-00013

Cited by 122 publications

(80 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…23 Suboptimal adherence has been associated with injection behaviours among current IDUs and social instability among former IDUs. 25 Social instability and differentiation between former and current IDU status was not Baseline VL <100 000 copies/mL 1.00 1.00 ≥100 000 copies/mL 1.56 (1.35-1.81) <0.0001 1.32 (1.13-1.55) <0.001…”

Section: Discussionmentioning

confidence: 95%

Increased mortality among Indigenous persons in a multisite cohort of people living with HIV in Canada

Benoit

Younger

Beaver

et al. 2017

Can J Public Health

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 95%

Increased mortality among Indigenous persons in a multisite cohort of people living with HIV in Canada

Benoit

Younger

Beaver

et al. 2017

Can J Public Health

View full text Add to dashboard Cite

“…10 Expanding availability of drug maintenance treatments could also be a way to improve social and psychological stability in this population and then access to HCV treatment. In any event, more attention should also be devoted to these patients to provide them a multidisciplinary approach, including HIV specialists, HCV specialists, psychologists, social workers, and community-based organizations, to optimize their access to HCV care whenever possible.…”

Section: Resultsmentioning

confidence: 99%

“…10 Using longitudinal data from the same cohort, we aimed to identify factors associated with the performance of liver biopsy in HIV-HCV coinfected injecting drug users (IDUs).…”

Section: Introductionmentioning

confidence: 99%

Factors Associated with Liver Biopsy Performance in HCV-HIV Coinfected Injecting Drug Users With HCV Viremia: Results From a Five-Year Longitudinal Assessment

Rey¹,

Carrieri

Spire

et al. 2004

Journal of Urban Health: Bulletin of the New York Academy of Me

View full text Add to dashboard Cite

show abstract

“…Nonetheless, HIV-infected drug abusers have been reported to display high rates of medication noncompliance (80). Factors working against medication compliance include unpleasant medication side effects, complexity of many HIV medication regimens, slow progression of HIV symptoms, cognitive deficits in many HIV+ drug abusers, the irregular schedules kept by many drug abusers, stigma associated with positive HIV status, and strong motivation for denial of this life-threatening infection (81)(82)(83). The interrelated phenomena of non-adherence and drug resistance are thought to be the most important reasons for failed treatment (84).…”

Section: Anti-retroviral Therapy For Hivmentioning

confidence: 99%

A Perfect Platform: Combining Contingency Management with Medications for Drug Abuse

Carroll

Rounsaville

2007

The American Journal of Drug and Alcohol Abuse

View full text Add to dashboard Cite

Contingency management (CM) procedures, which provide concrete reinforcers or rewards contingent on verification of discrete targeted behaviors, such as drug-free urines, have been demonstrated to be effective in a number of clinical trials. However, to date there have been only a few that have capitalized on the unique strengths and capabilities of CM as an ideal platform to improve response to or address weaknesses of many pharmacotherapies used in the treatment of drug abuse. In this review, we describe the multiple potential uses of CM as a platform for pharmacotherapy, including reducing illicit drug use in the context of agonist therapies; fostering medication compliance with antagonists, aversive agents and HIV medications; fostering a period of abstinence prior to initiation of agents used to treat comorbid psychiatric conditions or in the context of vaccines to foster adequate periods of abstinence while titer levels are building; and to enhance the effectiveness of anticraving agents through additive or synergistic effects. Although its multiple strengths render it an almost perfect platform, CM does have some weaknesses that have limited its use to date, including cost, the short-term nature of its effects, and need for training. Future treatment development of CM as a medication platform needs to counter these issues by focusing on CM applications with large potential benefit, developing simple or automated methods for CM delivery and placing greater emphasis on the process of transitioning away from formal CM treatment. KeywordsContingency management; medication compliance; medication trials; study design There has been enormous progress in recent years in the identification of empirically-supported behavioral (1) and pharmacological (2,3) treatments for a range of drug use disorders. However, despite growing consensus that combined treatments are often the more effective than monotherapies (4,5), the bulk of the literature is based on trials in which a single treatment is systematically varied, and simultaneous testing of combined treatments is comparatively rare (6). There remains much room for improvement, however, as even for our most effective therapies response is often only partial or transient for many patients, while others fail to respond at all. Furthermore, the potential effectiveness of many behavioral and pharmacologic

show abstract

Nonadherence Among HIV-Infected Injecting Drug Users: The Impact of Social Instability

Cited by 122 publications

References 24 publications

Increased mortality among Indigenous persons in a multisite cohort of people living with HIV in Canada

Increased mortality among Indigenous persons in a multisite cohort of people living with HIV in Canada

Factors Associated with Liver Biopsy Performance in HCV-HIV Coinfected Injecting Drug Users With HCV Viremia: Results From a Five-Year Longitudinal Assessment

A Perfect Platform: Combining Contingency Management with Medications for Drug Abuse

Contact Info

Product

Resources

About